570 related articles for article (PubMed ID: 28503750)
1. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
Khoo J; Hsiang JC; Taneja R; Koo SH; Soon GH; Kam CJ; Law NM; Ang TL
Liver Int; 2019 May; 39(5):941-949. PubMed ID: 30721572
[TBL] [Abstract][Full Text] [Related]
3. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
[TBL] [Abstract][Full Text] [Related]
4. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive lifestyle intervention
Deibert P; Lazaro A; Schaffner D; Berg A; Koenig D; Kreisel W; Baumstark MW; Steinmann D; Buechert M; Lange T
World J Gastroenterol; 2019 Mar; 25(9):1116-1131. PubMed ID: 30862999
[TBL] [Abstract][Full Text] [Related]
6. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
[TBL] [Abstract][Full Text] [Related]
8. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Feng WH; Bi Y; Li P; Yin TT; Gao CX; Shen SM; Gao LJ; Yang DH; Zhu DL
J Diabetes Investig; 2019 Mar; 10(2):399-407. PubMed ID: 29957886
[TBL] [Abstract][Full Text] [Related]
9. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
10. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
13. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study.
Yari Z; Rahimlou M; Eslamparast T; Ebrahimi-Daryani N; Poustchi H; Hekmatdoost A
Int J Food Sci Nutr; 2016 Jun; 67(4):461-9. PubMed ID: 26983396
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
He Q; Sha S; Sun L; Zhang J; Dong M
Biochem Biophys Res Commun; 2016 Aug; 476(4):196-203. PubMed ID: 27208776
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review.
Golabi P; Locklear CT; Austin P; Afdhal S; Byrns M; Gerber L; Younossi ZM
World J Gastroenterol; 2016 Jul; 22(27):6318-27. PubMed ID: 27468220
[TBL] [Abstract][Full Text] [Related]
17. Exercise-Induced Weight Loss is More Effective than Dieting for Improving Adipokine Profile, Insulin Resistance, and Inflammation in Obese Men.
Khoo J; Dhamodaran S; Chen DD; Yap SY; Chen RY; Tian RH
Int J Sport Nutr Exerc Metab; 2015 Dec; 25(6):566-75. PubMed ID: 26011919
[TBL] [Abstract][Full Text] [Related]
18. Effects of a combined intervention with a lentil protein hydrolysate and a mixed training protocol on the lipid metabolism and hepatic markers of NAFLD in Zucker rats.
Martínez R; Kapravelou G; Donaire A; Lopez-Chaves C; Arrebola F; Galisteo M; Cantarero S; Aranda P; Porres JM; López-Jurado M
Food Funct; 2018 Feb; 9(2):830-850. PubMed ID: 29364302
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ; Hull D; Guo K; Barton D; Hazlehurst JM; Gathercole LL; Nasiri M; Yu J; Gough SC; Newsome PN; Tomlinson JW
J Hepatol; 2016 Feb; 64(2):399-408. PubMed ID: 26394161
[TBL] [Abstract][Full Text] [Related]
20. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
